The overexpression of this protein in poorly differentiated lung adenocarcinomas and the elevated expression of the phosphorylated forms may offer a new target for drug- or gene-directed therapy and may have potential utility as a tumor marker.

mutation of KRAS E2 is positively associated with expression level of STMN1 in non-small cell lung cancer.

The mRNA expression level of STMN1, TOP2A and ERCC1 are correlated with non-small cell lung carcinoma pathology type in Chinese patients.

High stathmin 1 expression is associated with lung cancer.

SNP in STMN1 gene may have a potential predictive role in taxane-based chemotherapy in advanced non-small cell lung cancer.

Increased stathmin correlated with pathologic grade, lymphatic invasion, advanced stage and poor survival of non-small cell lung cancer (NSCLC), which indicated that stathmin could serve as a potential biomarker of NSCLC

STMN1 expression was associated with an unfavorable overall survival and disease-free proportion, and was an independent unfavorable prognostic factor for lung Adenocarcinoma, even when restricted to stage I.

High STMN1 expression is Associated with cancer Progression and Chemo-Resistance in lung Squamous Cell Carcinoma.

Stathmin-1 expression is significantly higher in high-grade lung neuroendocrine tumor (HGNET) tissues than in non-small cell lung cancer (NSCLC) tissues